Background: A number of new assays with different measuring principles are available to measure VWF GPIb-binding activity, but little is known about how these assays might behave differently for subtypes of VWD. Objectives: The COMPASS-VWF study was designed to compare all available VWF GPIb-binding activity assays for von Willebrand factor. We specifically searched for particular assay behavior differences. Patients/Methods To sort out random differences from systematic assay behavior deviations, all assays were performed in different laboratories on the same samples in a blinded fashion. Samples from 53 normal controls and 42 well-characterized VWD patients were re-analysed in this study to dissect assay-specific discrepancies. Results: No assay behavior differences were found for 53 normal controls. For VWD patients, we found the following systematic assay behavior patterns: (i) All ELISA assays for VWF:GPIbR as well as VWF:GPIbM are insensitive to detect the low VWF activity of VWD type 2B patients with loss of HMW multimers. (ii) VWF:Ab assay reports higher activity for the p.V1665E mutation than all other assays, and (iii) all ristocetin-based assays (including VWF:RCo using fixed platelets) but the AcuStar assay report discrepantly low VWF activity for the p.P1467S polymorphism. No systematic assay-specific difference was observed for either the particle agglutination VWF:GPIbM assay, or the AcuStar assay using magnetic beads. Conclusions: Different assay principles may lead to discrepant results for certain VWD types or mutations. Therefore, a more extensive study for a large number of patients is needed to better characterise the incidence and relevance of such assay specific differences.

Comparison of von Willebrand factor platelet-binding activity assays: ELISA overreads type 2B with loss of HMW multimers / A. Szederjesi, L. Baronciani, U. Budde, G. Castaman, P. Colpani, A.S. Lawrie, Y. Liu, R. Montgomery, F. Peyvandi, R. Schneppenheim, J. Patzke, I. Bodó. - In: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. - ISSN 1538-7933. - (2020). [Epub ahead of print]

Comparison of von Willebrand factor platelet-binding activity assays: ELISA overreads type 2B with loss of HMW multimers

L. Baronciani
Secondo
;
F. Peyvandi
;
2020

Abstract

Background: A number of new assays with different measuring principles are available to measure VWF GPIb-binding activity, but little is known about how these assays might behave differently for subtypes of VWD. Objectives: The COMPASS-VWF study was designed to compare all available VWF GPIb-binding activity assays for von Willebrand factor. We specifically searched for particular assay behavior differences. Patients/Methods To sort out random differences from systematic assay behavior deviations, all assays were performed in different laboratories on the same samples in a blinded fashion. Samples from 53 normal controls and 42 well-characterized VWD patients were re-analysed in this study to dissect assay-specific discrepancies. Results: No assay behavior differences were found for 53 normal controls. For VWD patients, we found the following systematic assay behavior patterns: (i) All ELISA assays for VWF:GPIbR as well as VWF:GPIbM are insensitive to detect the low VWF activity of VWD type 2B patients with loss of HMW multimers. (ii) VWF:Ab assay reports higher activity for the p.V1665E mutation than all other assays, and (iii) all ristocetin-based assays (including VWF:RCo using fixed platelets) but the AcuStar assay report discrepantly low VWF activity for the p.P1467S polymorphism. No systematic assay-specific difference was observed for either the particle agglutination VWF:GPIbM assay, or the AcuStar assay using magnetic beads. Conclusions: Different assay principles may lead to discrepant results for certain VWD types or mutations. Therefore, a more extensive study for a large number of patients is needed to better characterise the incidence and relevance of such assay specific differences.
Blood Coagulation Disorders; Clinical Laboratory Techniques; Enzyme-linked Immunosorbent Assay; von Willebrand Disease; von Willebrand Factor;
Settore MED/09 - Medicina Interna
2020
23-giu-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
jth.14971.pdf

Open Access dal 24/06/2021

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 12.31 MB
Formato Adobe PDF
12.31 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/744878
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 3
social impact